Basel, Switzerland, 13 September 2016 – Lonza announced today that it has closed the acquisition of InterHealth Nutraceuticals, Inc. (“InterHealth”), a leader in research, development, manufacture and marketing of proprietary, value-added nutritional ingredients for use in dietary supplements, based in Benicia, CA (USA) from Kainos Capital.
The InterHealth business will become part of Lonza’s Consumer Care Business Unit, but will retain its facilities and employees. The combination of the two businesses allows Lonza to offer InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is revolutionizing the joint-health segment.
“We are looking forward to welcoming the highly capable team to our Lonza family. They nicely complement our offerings and will be joining us in our quest to becoming the world’s leading and most-trusted supplier to the pharmaceutical, biotech and specialty ingredients markets.” said Richard Ridinger, Lonza’s Chief Executive Officer. “Lonza will be able to harness the proven management and branding capabilities and leverage them to a global level.”
Lonza acquired InterHealth for a total transaction price of up to USD 300 million split into an upfront payment and an earn-out payment. The transaction is expected to be immediately accretive to Lonza’s earnings.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
InterHealth Nutraceuticals researches, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. The company’s products include UC-II(r) for addressing joint discomfort; Super CitriMax(r), a weight loss and satiety ingredient; Meratrim(r) for weight management; Relora(r) for stress management; ChromeMate(r) and Zychrome(r) for blood sugar and insulin control; and CardiaSlim(r) for healthy cholesterol support. In addition, InterHealth offers 7-Keto(r), Sytrinol(r), LOWAT(r), Aller-7(r), OptiBerry(r), L-OptiZinc(r), Protykin(r) and ZMA(r). For more information about InterHealth and its products, visit www.interhealthusa.com.
Lonza Contact Information
|Lonza Group Ltd||Lonza Group Ltd||Lonza Group Ltd|
|Head Investor Relations||Head Corporate Communications||Head External Communications|
|Dirk Oehlers||Dominik Werner||Constance Ward|
|Tel +41 61 316 8540||Tel +41 61 316 8798||Tel +41 61 316 8840|
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
Office: 5451 Industrial Way
Benicia, CA 94510